Klingemann H G
Division of Hematology, Vancouver General Hospital, British Columbia, Canada.
Leuk Lymphoma. 1992 Dec;8(6):421-9. doi: 10.3109/10428199209051024.
Relapse after marrow transplantation occurs despite total body irradiation and high doses of chemotherapy used to prepare the recipient. Recurrence rate is particularly high after autologous transplantation. In order to eliminate minimal residual disease persistent after marrow grafting, immunotherapy is currently being explored as a treatment modality that is non-cross-reactive with radiation and chemotherapy. This review describes first clinical results on the use of interferons and interleukin-2 in marrow transplant recipients as well as attempts to induce graft-versus-leukemia effects.
尽管对接受者进行了全身照射和高剂量化疗以准备骨髓移植，但移植后仍会复发。自体移植后的复发率尤其高。为了消除骨髓移植后持续存在的微小残留病，目前正在探索免疫疗法，作为一种与放疗和化疗无交叉反应的治疗方式。这篇综述描述了在骨髓移植受者中使用干扰素和白细胞介素-2的首批临床结果，以及诱导移植物抗白血病效应的尝试。
